GlassScriptPhysician profile
Britt A Benn
NPI 1497921100
$11,154.07
in general payments reported to CMS, 2019-2025
62 companies · $2,024 in 2025
The $2,024 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,417 · 2022: $2,848 · 2023: $2,176 · 2024: $2,688 · 2025: $2,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,048 · Education: $841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,047.92 |
| Education | $840.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,439.90 | 2021-2025 | Rybrevant, Darzalex, Erleada |
| Astrazeneca Pharmaceuticals LP | $1,425.12 | 2021-2025 | Enhertu, Lynparza, Tagrisso |
| Daiichi Sankyo INC. | $661.32 | 2021-2025 | Enhertu, Vanflyta, Injectafer |
| Seagen INC. | $649.82 | 2021-2025 | Tivdak, Adcetris, Tukysa |
| Merck Sharp & Dohme LLC | $628.24 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $625.46 | 2021-2025 | |
| Incyte Corporation | $422.31 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Astellas Pharma US INC | $380.73 | 2022-2025 | Padcev, Vyloy, Xospata |
| E.R. Squibb & Sons, L.L.C. | $376.97 | 2021-2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $372.83 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $368.71 | 2021-2025 | |
| Abbvie INC. | $327.28 | 2022-2025 | |
| Genzyme Corporation | $308.59 | 2021-2025 | |
| Amgen INC. | $277.47 | 2021-2025 | Lumakras |
| Glaxosmithkline, LLC. | $234.64 | 2022-2025 | Ojjaara |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Britt Benn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.